EMBL Australia

EMBL Australia group leader Professor Max Cryle was part of an international team that reconstructed ancestral antibiotics to learn more about how they work in order to produce new antibiotics to combat the growing threat of antimicrobial resistance. Published in Nature Communications, this vital information will inform the development of next-generation superbug treatments.

EMBL Australia group leader Mikaël Martino has co-founded protein-engineering company Orio Therapeutics.

On a recent visit to EMBL Heidelberg, Ian Smith, Chair of the EMBL Australia Council, spoke about the synergies between EMBL and EMBL Australia, opportunities for collaboration and ideas for exciting future programs.

Michelle Boyle – an EMBL Australia group leader and Snow Medical Fellow based at the Burnet Institute – and Burnet Institute CEO and Director Brendan Crabb share their thoughts on the malaria vaccine newly recommended by the World Health Organisation in an article for The Conversation.

EMBL Australia group leaders Associate Professor Richard Morris, Associate Professor Yann Gambin & Dr Qi Zhang have each been awarded Discovery Project grants, totalling almost $1.7m collectively.

News this quarter:

• Dr Qi Zhang joins EMBL Australia as group leader at SAiGENCI
• Australian NCRIS health groups & European counterparts unite
• Group leader reviews for Richard Morris and Eduardo Eyras a success
• Dodgem car-like bumping helps vesicular transport system deliver on time
• Professor Max Cryle promoted
• Register to attend our popular postgrad symposium
• Read our Partner Laboratory Network 2022 Highlights Report
• Get to Know… Dr Qi Zhang

And more:

• Job opportunities
• Student opportunities
• Upcoming events
• Recent publications

Dr Qi Zhang will commence in December as the first EMBL Australia Group Leader to be based at the South Australian immunoGENomics Cancer Institute (SAiGENCI), Adelaide.

A study co-led by group leader Dr Senthil Arumugam and published in Nature Communications reveals a novel mechanism by which cells control the orderly & timely delivery of molecular cargo.

We’re excited to announce that Dr Qi Zhang will be the first EMBL Australia group leader to be hosted at the South Australian immunoGENomics Cancer Institute.

The past year marked a significant period of reconnection and scientific advancement within our research community. It was a year of scientific success for many in our PLN, with members involved in securing $66.7 million in competitive grants to support their groundbreaking and collaborative research. This injection of additional funding will help shape the future of healthcare, not just in Australia but worldwide, by supporting the varied and cutting-edge research happening across the Partner Laboratory Network.